A Phase 1 Dose-Escalation Study of LY2523355 in Patients With Advanced Cancer.
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2018
At a glance
- Drugs Litronesib (Primary) ; Pegfilgrastim
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly
- 16 Jul 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov record.
- 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 16 Aug 2011 Planned end date changed from 1 Jun 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.